4.23
+1.275(+43.22%)
Currency In USD
| Previous Close | 2.95 |
| Open | 4 |
| Day High | 4.39 |
| Day Low | 3.79 |
| 52-Week High | 7.55 |
| 52-Week Low | 2.12 |
| Volume | 52.07M |
| Average Volume | 4.03M |
| Market Cap | 421.06M |
| PE | -6.06 |
| EPS | -0.7 |
| Moving Average 50 Days | 5.28 |
| Moving Average 200 Days | 4.54 |
| Change | 1.29 |
If you invested $1000 in Aquestive Therapeutics, Inc. (AQST) since IPO date, it would be worth $264.49 as of February 02, 2026 at a share price of $4.245. Whereas If you bought $1000 worth of Aquestive Therapeutics, Inc. (AQST) shares 5 years ago, it would be worth $786.11 as of February 02, 2026 at a share price of $4.245.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
GlobeNewswire Inc.
7 hours ago
Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026 with significant cashReiterates plans to submit i
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
GlobeNewswire Inc.
Jan 09, 2026 12:00 PM GMT
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is ongoing and no final FDA decision h
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
WARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science an